clinical trial · NCT04882098
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
Janssen Research & Development, LLC·phase3·active not recruiting·n = 1,054
Arthritis, PsoriaticGuselkumabPlacebo
brief summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
started
Jun 17, 2021
primary completion
Dec 30, 2024
completion
Oct 6, 2027
last updated
Aug 20, 2026
official title
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol